EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling

Federica Papaccio, Ramona Marrapodi iD, Laura Eibenschutz, Andrea D'Arino iD, Silvia Caputo, Alberto Marini, Simona Scano, Arianna Presaghi iD, Carlo Cota, Elisa Melucci iD, Stefano Scalera iD, Emilia Migliano iD und 3 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms27010068 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Federica Papaccio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chian…. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Skin Neoplasms, Smoothened Receptor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Basal cell carcinoma (BCC) is the most common skin cancer, predominantly affecting sun-exposed areas. It typically grows slowly and rarely metastasizes, though untreated cases can cause significant tissue destruction and morbidity. Its pathogenesis primarily involves dysregulation of the Hedgehog (HH) signaling pathway, mainly through mutations in PTCH1 or SMO genes, leading to chronic activation of downstream GLI transcription factors. Accordingly, current targeted therapies for locally advanced, unresectable, or metastatic BCC focus on SMO inhibition, using orally administered drugs such as vismodegib and sonidegib. Although these therapies have shown success, many patients develop resistance, with about 50% harboring mutated SMO. In numerous cases, genetic determinants (sometimes pre-existing) of resistance remain unidentified, complicating patient management. Here, we report a case of a 58-year-old female with advanced BCC who initially exhibited a favorable response to sonidegib but developed resistance after approximately one year. This resistance was not attributable to the acquired mutations in SMO but rather to intra-tumor heterogeneity and additional mutations in critical driver genes, including TP53, APC, FGFR1 and NOTCH1, which likely enable HH pathway inhibition. To our knowledge, this is the first report documenting a sonidegib resistance mechanism in BCC that is independent of HH pathway mutations. This case highlights the complexity of resistance mechanisms to HH inhibitors and underscores the critical need for comprehensive molecular tumor profiling prior to initiating targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaSkin NeoplasmsSmoothened ReceptorDrug Resistance, NeoplasmAntineoplastic AgentsHumansFemalePyridinesBiphenyl CompoundsMutationSignal TransductionHedgehog Proteins

Stichwörter der Autor:innen

basal cell carcinomadrug resistancehedgehog pathwaytargeted therapies

Substanzen

Smoothened ReceptorsonidegibPyridinesBiphenyl CompoundsSMO protein, humanAntineoplastic AgentsHedgehog Proteins

Autor:innen und Institutionen

  • Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Oncologic and Preventative Dermatology, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Department of Plastic and Regenerative Surgery, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Genetic Research, Molecular Biology and Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Department of Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Biostatistics, Bioinformatics and Clinical Trial Center, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.

ORCID-Profile: Ramona Marrapodi, Andrea D'Arino, Arianna Presaghi, Elisa Melucci, Stefano Scalera, Emilia Migliano, Barbara Bellei

Förderung

  • Italian Ministry of Health

Zitieren

APA

Papaccio, F., Marrapodi, R., Eibenschutz, L., D'Arino, A., Caputo, S., Marini, A., Scano, S., Presaghi, A., Cota, C., Melucci, E., Scalera, S., Migliano, E., Maugeri-Saccà, M., Frascione, P., & Bellei, B. (2025). Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010068

Vancouver

Papaccio F, Marrapodi R, Eibenschutz L, D'Arino A, Caputo S, Marini A, et al. Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010068

BibTeX
@article{Papaccio2025,
  author = {Papaccio, Federica and Marrapodi, Ramona and Eibenschutz, Laura and D'Arino, Andrea and Caputo, Silvia and Marini, Alberto and Scano, Simona and Presaghi, Arianna and Cota, Carlo and Melucci, Elisa and Scalera, Stefano and Migliano, Emilia and Maugeri-Saccà, Marcello and Frascione, Pasquale and Bellei, Barbara},
  title = {Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms27010068}
}
Kostenlos starten →